BACKGROUND Pre-clinical data show that overlapping scaffold segments show delayed healing and strut coverage compared to nonoverlapping scaffold segments. Little is known whether this may have an impact on clinical outcome.
RESULTS
No differences in baseline patient and lesion characteristics between both patient groups were noted, apart from the significant longer lesion length in the overlapping scaffold group (16.7AE7.3 versus 11.6AE4.4 mm, [p<0.0001; 95% CI: 3.7-6.4]) and subsequently less lesion type B1 and more B2. Furthermore, more patients were treated for stable angina in the overlapping scaffold group (72% versus 54%, p¼0.0003). In the overlapping scaffold group 41/125 (33%) lesions were > 20 mm long, compared to 33/734 (5%) lesions in the nonoverlapping group, p<0.0001. The 1 year clinical outcome is summarized in the table below. Scaffold Thrombosis is reported according ARC and Myocardial Infarction according protocol definitions.
Overlapping
Non-overlapping P value properties. The drug dose is 5 mg per mm of scaffold length; the device is available in multiple diameters (2.5 -3.5 mm) and lengths (14, 18 and 28 mm). The DESolve Nx study is multi-center evaluation of the safety and efficacy of the DESolve NEBCSS in patients with single, de novo, native coronary artery lesions.
METHODS A total of 126 patients were enrolled in this prospective registry. Patients receiving the study device were analyzed for multiple clinical endpoints including: device and procedure success; Major Adverse Cardiac Events (MACE), a composite endpoint of cardiac death, target vessel MI, or clinically-indicated target lesion revascularization (CI-TLR); Target Vessel Revascularization, (CI-TVR) and stent thrombosis assessed at 1, 6 and annually to 5 years. All patients underwent angiographic assessment at 6 months and a subset of patients underwent IVUS and OCT assessment also at 6 months and imaging 12 months using multislice computed tomography (MSCT). Additionally, at single centers, multi-modality imaging was completed at 18 months and 3 years. BACKGROUND The SYNTAX revascularization index (SRI), representing the percentage of revascularized myocardium, has been shown to be a strong independent predictor of adverse ischemic events after percutaneous coronary intervention (PCI); however, its predictive capability among patients with complex coronary artery disease (CAD) undergoing PCI with second-generation everolimus-eluting stents (EES) remains unexplored. We sought to evaluate the impact of incomplete revascularization as assessed by the SRI on 2-year adverse ischemic events in a population of patients with complex CAD undergoing EES-PCI.
RESULTS
METHODS Among 1900 patients enrolled in A Registry to Evaluate Safety and Effectiveness of Everolimus Drug Eluting Stent for Coronary Revascularization (SEEDS), SRI was available in 1851. Patients were stratified into three groups (SRI¼100%, SRI 50 to 99%, and SRI <50%), according to the proportion of revascularized myocardium. Mortality and major adverse cardiac events (MACE) were compared between groups.
